ArticleAdvanced healthcare materials2025
Biomimetic Glycosaminoglycan-Analog Hydrogel for Improved Embolization of Aneurysms: Environment-Selective Swelling.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomimetic Glycosaminoglycan-Analog Hydrogel for Improved Embolization of Aneurysms: Environment-Selective Swelling.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Injectable hydrogels are promising biomaterials for treating aneurysms, life-threatening blood-filled saccular lesions, enabling complete filling of the aneurysm and supporting tissue repair. Yet, the challenge is to enable clinical translation as hydrogels must not protrude into the parent vessel, nor migrate from the aneurysm cavity. Here, injectable, negatively-charged, biologically and mechanically compatible hydrogels with environment-sensitive swelling capabilities that cease swelling upon contact with blood are developed. Hydrogels are fabricated by copolymerizing sodium 2-acrylamido-2-methylpropanesulfonic acid (NaAMPS) and 3-sulfopropyl acrylate (KSPA) by using polyethylene glycol diacrylate (PEGDA). Three formulations (2%, 4%, and 6%) demonstrating a wide range of physiological-relevant stiffnesses are fabricated. The selected mechano-compatible 4% hydrogel exhibits a suitable swelling pressure (125 kPa) and supports high endothelial cell viability (> 75%). Importantly, the hydrogel demonstrates a significant differential swell with respect to blood (30 ± 4%), plasma (58 ± 3%), and PBS (82 ± 2%). This environment-selective swelling, upon exposure to blood, results in minimal directional swelling toward the parent artery, which can improve embolization outcomes. Hydrogel embolization in 3D-printed aneurysm models subjected to physiological blood flow shows no protrusion toward the main artery while completely blocking flow into the aneurysm. This approach provides promising opportunities for efficient embolization of a variety of aneurysms and vascular malformations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.